What You Should Know:
– Cleveland Clinic and Dyania Health have announced a collaboration to integrate Dyania’s Synapsis™ AI platform across Cleveland Clinic’s clinical research enterprise.
– The partnership, which follows successful pilot programs in cardiology, oncology, and neurology, aims to accelerate clinical trial recruitment by using medically trained large language models (LLMs) to speed up and scale patient identification for research studies. The ultimate goal is to provide more patients with faster access to potentially beneficial therapies.
Clinical Trial Recruitment Barriers
Clinical trial recruitment remains a significant barrier to scientific progress, with approximately 80% of trials failing to meet their enrollment timelines and 50% of trial sites failing to enroll any patients. By using AI to automate chart review and rapidly identify eligible participants, Cleveland Clinic and Dyania Health are addressing these bottlenecks and expanding patient access to potentially life-saving therapies.
Pilot Programs Demonstrate Speed and Accuracy
The collaboration’s pilot programs have shown promising results. In a trial for melanoma, a research team compared the Synapsis AI platform against two experienced research nurses. The AI technology identified an appropriate patient in 2.5 minutes with 96% accuracy, compared to a melanoma-specialized nurse who took 427 minutes with 95% accuracy. An oncology research nurse took 540 minutes with 88% accuracy. These results, which were presented at the American Society of Clinical Oncology annual meeting, demonstrate the platform’s speed, scalability, and clinical-grade accuracy.
Similarly, in a pilot for the DepleTTR-CM trial for a rare heart disease, the platform analyzed over 1.2 million patient records and identified 30 eligible participants in one week. In comparison, routine recruitment over 90 days identified only 14 patients for screening. The platform also identified patients from a broader range of clinical sites, which widens patient representation and community engagement.
As part of the ongoing collaboration, the teams are also validating and deploying new applications of the technology in neurology. They are working to speed up access to care and clinical trials for complex neurodegenerative conditions.
“Academic medical centers like Cleveland Clinic are home to some of the most advanced clinical research in the world, yet they often face significant challenges when trying to connect patients to trials – challenges rooted in complexity, time and fragmented data,” said Eirini Schlosser, Founder and CEO of Dyania Health. “Through our collaboration with Cleveland Clinic, we are creating a new standard where AI enables faster connections between patients and potentially life-changing trials. This work is deeply personal. It is about ensuring that no opportunity for progress is lost in the complexity of data, and that innovation reaches people when it matters most.”
